Octagon Capital Advisors
Latest statistics and disclosures from Octagon Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DNTH, COGT, ABVX, ALMS, DFTX, and represent 48.44% of Octagon Capital Advisors's stock portfolio.
- Added to shares of these 10 stocks: DFTX (+$46M), MIRM (+$31M), XENE (+$29M), TERN (+$28M), IRON (+$17M), Aktis Oncology (+$17M), CNTX (+$14M), ALMS (+$6.6M), OCUL, KALV.
- Started 8 new stock positions in TERN, IRON, Aktis Oncology, XENE, DFTX, MIRM, CNTX, CATX.
- Reduced shares in these 10 stocks: DNTH (-$39M), MNMD (-$30M), CGON (-$25M), CDTX (-$22M), RAPT (-$19M), TRVI (-$16M), PHVS (-$14M), KYMR (-$9.2M), ABVX (-$8.8M), EVMN (-$8.2M).
- Sold out of its positions in CGON, CDTX, CRBP, MNMD, PEPG, RAPT.
- Octagon Capital Advisors was a net seller of stock by $-7.2M.
- Octagon Capital Advisors has $904M in assets under management (AUM), dropping by 9.70%.
- Central Index Key (CIK): 0001839435
Tip: Access up to 7 years of quarterly data
Positions held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 29 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Dianthus Therapeutics (DNTH) | 18.1 | $163M | -19% | 1.9M | 83.92 |
|
| Cogent Biosciences (COGT) | 10.0 | $91M | 2.4M | 38.49 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 8.3 | $75M | -10% | 677k | 111.35 |
|
| Alumis (ALMS) | 6.9 | $62M | +11% | 2.8M | 22.03 |
|
| Definium Therapeutics Com Shs (DFTX) | 5.1 | $46M | NEW | 2.4M | 18.90 |
|
| Arrivent Biopharma (AVBP) | 5.0 | $46M | 2.0M | 23.07 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 4.4 | $40M | 8.9M | 4.47 |
|
|
| Kymera Therapeutics (KYMR) | 3.9 | $35M | -20% | 425k | 83.29 |
|
| Mirum Pharmaceuticals (MIRM) | 3.5 | $31M | NEW | 339k | 92.38 |
|
| Bioage Labs (BIOA) | 3.4 | $31M | +9% | 1.7M | 17.49 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 3.3 | $30M | 750k | 39.72 |
|
|
| Kalvista Pharmaceuticals (KALV) | 3.2 | $29M | +13% | 1.5M | 20.13 |
|
| Xenon Pharmaceuticals (XENE) | 3.2 | $29M | NEW | 490k | 58.15 |
|
| Terns Pharmaceuticals (TERN) | 3.1 | $28M | NEW | 530k | 52.72 |
|
| Ocular Therapeutix (OCUL) | 3.0 | $27M | +20% | 3.2M | 8.47 |
|
| Palisade Bio (PALI) | 2.0 | $18M | +7% | 10M | 1.75 |
|
| Trevi Therapeutics (TRVI) | 2.0 | $18M | -47% | 1.5M | 11.93 |
|
| Disc Medicine (IRON) | 1.9 | $17M | NEW | 270k | 63.94 |
|
| Aktis Oncology | 1.9 | $17M | NEW | 961k | 17.89 |
|
| Context Therapeutics (CNTX) | 1.5 | $14M | NEW | 5.3M | 2.62 |
|
| Precision Biosciences Com New (DTIL) | 1.4 | $12M | +16% | 2.2M | 5.50 |
|
| Dbv Technologies S A Sponsored Ads (DBVT) | 1.3 | $12M | 574k | 20.89 |
|
|
| Unicycive Therapeutics Com New (UNCY) | 0.7 | $6.6M | 1.0M | 6.58 |
|
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.7 | $6.4M | -31% | 719k | 8.95 |
|
| Lexeo Therapeutics (LXEO) | 0.7 | $6.3M | -36% | 1.1M | 5.74 |
|
| Pharvaris N V (PHVS) | 0.5 | $4.7M | -75% | 165k | 28.25 |
|
| Perspective Therapeutics Com New (CATX) | 0.4 | $3.3M | NEW | 792k | 4.17 |
|
| Evommune Com Shs (EVMN) | 0.4 | $3.3M | -71% | 144k | 22.99 |
|
| Gossamer Bio (GOSS) | 0.3 | $2.5M | -44% | 7.8M | 0.33 |
|
Past Filings by Octagon Capital Advisors
SEC 13F filings are viewable for Octagon Capital Advisors going back to 2020
- Octagon Capital Advisors 2026 Q1 filed May 15, 2026
- Octagon Capital Advisors 2025 Q4 filed Feb. 17, 2026
- Octagon Capital Advisors 2025 Q3 filed Nov. 14, 2025
- Octagon Capital Advisors 2025 Q2 filed Aug. 14, 2025
- Octagon Capital Advisors 2025 Q1 restated filed May 16, 2025
- Octagon Capital Advisors 2025 Q1 filed May 15, 2025
- Octagon Capital Advisors 2024 Q4 filed Feb. 14, 2025
- Octagon Capital Advisors 2024 Q3 filed Nov. 14, 2024
- Octagon Capital Advisors 2024 Q2 filed Aug. 14, 2024
- Octagon Capital Advisors 2024 Q1 filed May 15, 2024
- Octagon Capital Advisors 2023 Q4 filed Feb. 14, 2024
- Octagon Capital Advisors 2023 Q3 filed Nov. 14, 2023
- Octagon Capital Advisors 2023 Q2 filed Aug. 14, 2023
- Octagon Capital Advisors 2023 Q1 filed May 15, 2023
- Octagon Capital Advisors 2022 Q4 filed Feb. 14, 2023
- Octagon Capital Advisors 2022 Q3 filed Nov. 14, 2022